60 Degrees Pharmaceuticals Secures Exclusive License for Australian Chestnut Extract — 60 Degrees Pharmaceuticals, Inc.

Event summary

60 Degrees Pharmaceuticals signed an exclusive patent license agreement with Florida State University for non-prescription use of Australian Chestnut Extract.
The agreement allows large-scale extraction of castanospermine from Castanospermum australe seeds.
FDA issued a Non-Notification Letter on the Company’s New Dietary Ingredient Notification (NDIN) for Australian Chestnut Extract.
60 Degrees Pharma will meet with the FDA on July 1, 2026, to discuss the feedback and submit a revised NDIN.

The big picture

60 Degrees Pharmaceuticals is expanding its portfolio beyond vector-borne disease treatments into botanical supplements, leveraging an exclusive license for Australian Chestnut Extract. The strategic shift aligns with growing interest in natural health products, but success hinges on navigating FDA regulatory hurdles and scaling production efficiently. The company’s ability to commercialize this extract could open new revenue streams, though it remains to be seen how quickly it can overcome the current regulatory feedback.

What we're watching

Regulatory Clarity: How the FDA’s feedback will impact the timeline for market approval of Australian Chestnut Extract.
Production Scaling: The pace at which 60 Degrees Pharmaceuticals can scale up extraction and purification of castanospermine.
Market Potential: Whether the botanical supplement market can absorb a new non-prescription product derived from Australian Chestnut Extract.